 |
|
|
| |
ANRS 146 - GeSIDA 7211 OPTIMAL
Optimized Phase III Trial of Immuno-stimulation with Maraviroc, a CCR5 antagonist, combined with Anti Retroviral Therapy (cART) in advanced, Late diagnosed HIV-1 infected patients with an AIDS-defining event and/or CD4 counts > 200 cells/ mm3
|
| |
| |
Reported by Jules Levin
9th IAS Conference on HIV Science (IAS 2017), July 23-26, 2017, Paris
Yves Levy, Jean-Daniel Lelievre, Lambert Assoumou, Esther Aznar, Federico Pulido, Giuseppe Tambussi, Manuel Crespo, Agnes Meybeck, Jean-Michel Molina, Fanny Cardon, Constance Delaugerre, Remi Lancar, Lydie Beniguel, Dominique Costagliola and the OPTIMAL trial team
|
| |
|
|
|
|
|
